BRPI0412380A - benzenesulfonylamino compounds and pharmaceutical compositions containing these - Google Patents

benzenesulfonylamino compounds and pharmaceutical compositions containing these

Info

Publication number
BRPI0412380A
BRPI0412380A BRPI0412380-8A BRPI0412380A BRPI0412380A BR PI0412380 A BRPI0412380 A BR PI0412380A BR PI0412380 A BRPI0412380 A BR PI0412380A BR PI0412380 A BRPI0412380 A BR PI0412380A
Authority
BR
Brazil
Prior art keywords
compounds
disease
pharmaceutical compositions
compositions containing
type
Prior art date
Application number
BRPI0412380-8A
Other languages
Portuguese (pt)
Inventor
Thalaththani Ralalag Vedananda
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0412380A publication Critical patent/BRPI0412380A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMPOSTOS DE BENZENOSSULFONILAMINO E COMPOSIçõES FARMACêUTICAS QUE CONTêM ESSES COMPOSTOS". A presente invenção refere-se a compostos de fórmula (I) que proporcionam agentes farmacológicos que se ligam a Receptores Ativados por Proliferadores de Peroxissoma (PPARs). Conseqüentemente, os compostos da presente invenção são úteis para o tratamento de condições mediadas pela atividade de receptor PPAR em mamíferos. Essas condições incluem dislipidemia, hiperlipidemia, hipercolesteremia, aterosclerose, hipertrigliceridemia, insuficiência cardíaca, infarto do miocárdio, doenças vasculares, doenças cardiovasculares, hipertensão, obesidade, inflamação, artrite, câncer, doença de Alzheimer, distúrbios da pele, doenças respiratórias, distúrbios oftálmicos, doenças inflamatórias intestinais (IBDs), colite ulcerativa e doença de Crohn, e condições em que tolerância a glicose prejudicada, hiperglicemia e resistência à insulina estão implicadas, tais como diabetes tipo 1 e tipo 2, e Síndrome X."BENZENOSULFONYLAMINO COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS". The present invention relates to compounds of formula (I) which provide pharmacological agents that bind to Peroxisome Proliferator Activated Receptors (PPARs). Accordingly, the compounds of the present invention are useful for treating conditions mediated by PPAR receptor activity in mammals. These conditions include dyslipidemia, hyperlipidemia, hypercholesteremia, atherosclerosis, hypertriglyceridemia, heart failure, myocardial infarction, vascular disease, cardiovascular disease, hypertension, obesity, inflammation, arthritis, cancer, Alzheimer's disease, skin disorder, respiratory disease, ophthalmic disorder, inflammatory bowel diseases (IBDs), ulcerative colitis and Crohn's disease, and conditions in which impaired glucose tolerance, hyperglycemia and insulin resistance are implicated, such as type 1 and type 2 diabetes, and Syndrome X.

BRPI0412380-8A 2003-07-08 2004-07-07 benzenesulfonylamino compounds and pharmaceutical compositions containing these BRPI0412380A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48587003P 2003-07-08 2003-07-08
PCT/EP2004/007442 WO2005005421A1 (en) 2003-07-08 2004-07-07 Benzenesulfonylamino compounds and pharmaceutical compositions containing these compounds

Publications (1)

Publication Number Publication Date
BRPI0412380A true BRPI0412380A (en) 2006-09-19

Family

ID=34062103

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0412380-8A BRPI0412380A (en) 2003-07-08 2004-07-07 benzenesulfonylamino compounds and pharmaceutical compositions containing these

Country Status (9)

Country Link
US (1) US7538135B2 (en)
EP (1) EP1646628A1 (en)
JP (1) JP2009513523A (en)
CN (1) CN100447139C (en)
AU (1) AU2004255342C1 (en)
BR (1) BRPI0412380A (en)
CA (1) CA2531418A1 (en)
MX (1) MXPA06000118A (en)
WO (1) WO2005005421A1 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7816385B2 (en) * 2002-12-20 2010-10-19 High Point Pharmaceuticals, Llc Dimeric dicarboxylic acid derivatives, their preparation and use
NZ544784A (en) * 2003-07-28 2009-11-27 Reddys Lab Inc Dr Treatment and prevention of cardiovascular events using a beta-adrenergic receptor antagonist, a diuretic, an inhibitor of HMG CoA reductase, an inhibitor of the rennin-angiotensin system and asprin; wherein acidic and basic components are separated.
CA2610354C (en) 2005-05-31 2011-03-29 Pfizer Inc. Substituted aryloxy-n-bicyclomethyl acetamide compounds as vr1 antagonists
PE20070335A1 (en) 2005-08-30 2007-04-21 Novartis Ag SUBSTITUTE BENZIMIDAZOLES AND METHODS FOR THEIR PREPARATION
ATE513829T1 (en) 2005-10-06 2011-07-15 Sanofi Aventis BICYCLIC ARYLSULPHONIC ACID 1,3,4Ü-THIADIAZOLE-2-YL-AMIDES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS PHARMACEUTICALS
CA2624726A1 (en) 2005-10-06 2007-04-12 Sanofi-Aventis 4-oxy-n-[1 ,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals
WO2007039175A1 (en) 2005-10-06 2007-04-12 Sanofi-Aventis N-[1 ,3,4]-thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and their use as pharmaceuticals
US20070116756A1 (en) * 2005-11-23 2007-05-24 Dr. Reddy's Laboratories Limited Stable pharmaceutical compositions
DK2054397T3 (en) 2006-08-16 2016-01-18 J David Gladstone Inst A Testamentary Trust Established Under The Will Of J David Gladstone SMALL MOLECULAR INHIBITORS OF KYNURENIN-3-MONOOXYGENASE
EP2420494B1 (en) * 2006-08-16 2014-10-08 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Use of thiadiazole compounds as inhibitors of kynurenine-3-monooxygenase
JP4891111B2 (en) * 2007-02-16 2012-03-07 富士フイルム株式会社 Zoom lens
JP5361857B2 (en) 2007-03-23 2013-12-04 ファイザー・リミテッド Ion channel inhibitors
BRPI0821915A2 (en) 2007-12-26 2015-06-16 Sanofi Aventis Cyclic pyridyl-n- (1,3,4) -thiadiazol-2-yl-benzene sulfonamides, processes for their preparation and use as pharmaceuticals
MX2010011258A (en) 2008-04-14 2011-06-20 Univ Texas Small molecule inhibitors of the pleckstrin homology domain and methods for using same.
HRP20160967T1 (en) 2009-10-06 2016-10-07 Millennium Pharmaceuticals, Inc. Heterocyclic compounds useful as pdk1 inhibitors
US8491927B2 (en) 2009-12-02 2013-07-23 Nimble Epitech, Llc Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor
CN101774922B (en) * 2010-01-29 2012-12-26 浙江大学 2,3-dyhydroxyl parabens compound as well as preparation and application thereof
EP2734840B3 (en) 2011-07-20 2017-06-07 The Regents of the University of California Dual-pore device
US9187439B2 (en) 2011-09-21 2015-11-17 Inception Orion, Inc. Tricyclic compounds useful as neurogenic and neuroprotective agents
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9920992B2 (en) 2012-04-16 2018-03-20 Pyrotek, Inc. Molten metal scrap submergence apparatus
WO2014093988A2 (en) 2012-12-14 2014-06-19 Phusis Therapeutics, Inc. Methods and compositions for inhibiting cnksr1
MX2021012208A (en) 2013-10-04 2023-01-19 Infinity Pharmaceuticals Inc Heterocyclic compounds and uses thereof.
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
NZ724368A (en) 2014-03-19 2023-07-28 Infinity Pharmaceuticals Inc Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MA41139B1 (en) 2014-12-11 2026-02-27 Laboratoires Juvise Pharmaceuticals Pharmaceutical combination including ponesimod and its use in the treatment of multiple sclerosis
EP4056179A1 (en) 2014-12-11 2022-09-14 Actelion Pharmaceuticals Ltd Dosing regimen for ponesimod, a selective s1p1 receptor agonist
GB2533136A (en) * 2014-12-11 2016-06-15 Antabio Sas Compounds
US10227356B2 (en) 2015-04-20 2019-03-12 Phusis Therapeutics, Inc. Compounds, compositions and methods for inhibiting CNKSR1
EP4585268A3 (en) 2015-09-14 2025-10-15 Twelve Therapeutics, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
PL3458449T3 (en) 2016-05-20 2025-06-23 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3281937A1 (en) * 2016-08-09 2018-02-14 Dompé farmaceutici S.p.A. Sulfonamides as gpr40- and gpr120-agonists
CN110325531B (en) 2016-12-09 2022-05-27 泽农医药公司 Benzenesulfonamides and their use as therapeutic agents
CN115745910B (en) 2017-07-21 2025-05-27 安塔比奥公司 Chemical compounds
US10745392B2 (en) 2018-06-13 2020-08-18 Xenon Pharmaceuticals Inc. Benzenesulfonamide compounds and their use as therapeutic agents
KR20210054510A (en) 2018-08-31 2021-05-13 제논 파마슈티칼스 인크. Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents
MA53488A (en) 2018-08-31 2021-12-08 Xenon Pharmaceuticals Inc HETEROARYL SUBSTITUTED SULPHONAMIDE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL BLOCKERS

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2318731C (en) * 1998-01-29 2012-05-29 Tularik Inc. Ppar-gamma modulators
WO2000047209A1 (en) * 1999-01-19 2000-08-17 Tularik Inc. Methods of modulating uric acid levels
NZ515086A (en) 1999-04-28 2003-10-31 Aventis Pharma Gmbh Di-aryl acid derivatives as PPAR receptor ligands
US6298255B1 (en) * 1999-06-09 2001-10-02 Aspect Medical Systems, Inc. Smart electrophysiological sensor system with automatic authentication and validation and an interface for a smart electrophysiological sensor system
DE60029446T2 (en) * 1999-06-18 2007-02-08 Merck & Co., Inc. ARYLTHIAZOLIDEINDIONE AND ARYLOXAZOIDIDE DERIVATIVES
IL147308A0 (en) * 1999-06-30 2002-08-14 Tularik Inc Compounds for the modulation of pparγ activity and pharmaceutical compositions containing the same
WO2001082916A2 (en) * 2000-05-03 2001-11-08 Tularik Inc. Combination therapeutic compositions and methods of use
WO2002060388A2 (en) 2001-01-30 2002-08-08 Merck & Co., Inc. Acyl sulfamides for treatment of obesity, diabetes and lipid disorders
US20030092736A1 (en) * 2001-05-30 2003-05-15 Cheng Peter T. Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
TW200303742A (en) * 2001-11-21 2003-09-16 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
CN100447139C (en) 2008-12-31
US20070043020A1 (en) 2007-02-22
JP2009513523A (en) 2009-04-02
WO2005005421A1 (en) 2005-01-20
US7538135B2 (en) 2009-05-26
MXPA06000118A (en) 2006-04-27
AU2004255342A1 (en) 2005-01-20
CN1816546A (en) 2006-08-09
AU2004255342C1 (en) 2009-05-14
AU2004255342B2 (en) 2008-11-20
CA2531418A1 (en) 2005-01-20
EP1646628A1 (en) 2006-04-19

Similar Documents

Publication Publication Date Title
BRPI0412380A (en) benzenesulfonylamino compounds and pharmaceutical compositions containing these
BRPI0410779A (en) n-acyl nitrogen heterocycles as peroxisome proliferator activated receptor ligands
BR0214305A (en) Heterocyclic Compounds and Methods of Use
BRPI0414536A (en) organic compounds
CO2021008089A2 (en) Glp-1r agonists and their uses
AR123156A1 (en) GLP-1R AGONISTS AND THEIR USES
ZA202205346B (en) Glp-1 receptor agonist and use thereof
BRPI0518425A2 (en) pharmaceutical composition comprising omega-3 fatty acids and par agonist and / or antagonist; and unit dosage form pharmaceutical composition comprising fenofibrate and solvent system
BR112021020335A2 (en) glp-1r agonists and uses thereof
CY1121423T1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF A METABOLIC SYNDROME
EA200970342A1 (en) GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS CONTAINING SUCH CONNECTIONS AND APPLICATIONS
MX2016015182A (en) ANTIDIABETIC TRICICLIC COMPOUNDS.
PE20050249A1 (en) NEW CYANOPYRROLIDES AND PROCEDURE FOR THEIR PREPARATION AS MEDICINES
ECSP088120A (en) DERIVATIVES OF PIRIDAZINONA AS AGONISTS OF THE RECEPTOR OF THE HORMONE TIROIDEA
MX2009008159A (en) Compounds and compositions as modulators of gpr119 activity.
MX2009006795A (en) Compounds having both angiotensin ii receptor antagonism and ppary activating activities.
BRPI0717156B8 (en) sodium glucose co-transporter 2 inhibitors and pharmaceutical composition comprising them
CL2007003874A1 (en) COMPOUNDS DERIVED FROM BENZAMIDA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO TREAT CARDIOVASCULAR DISEASES, HYPERTENSION, ATEROSCLEROSIS, RESTENOSIS, ICTUS, HEART FAILURE, ISCHEMICAL INJURY, HYPERTENSION
BRPI1013645A2 (en) antibody drug conjugate and its pharmaceutical composition
EA201100910A1 (en) TREATMENT OF INFLAMMATORY DISEASES OF THE INTESTINE BETA-DEFENSINS OF MAMMALS
CL2011001848A1 (en) Compounds derived from pyrimidine fused to a 5-membered heterocycle; angiotensin ii receptor antagonist, peroxisome proliferator receptor agonist; pharmaceutical composition; and use of the compounds in the treatment of circulatory diseases such as hypertension, heart disease, arteriosclerosis, among others.
BRPI0821266B8 (en) TRIAZOL- SUBSTITUTED ARILAMIDE DERIVATIVES AND THEIR USE AND PHARMACEUTICAL COMPOSITION
EP2401263A4 (en) SUBSTITUTED AZOLE DERIVATIVES, PHARMACEUTICAL COMPOSITION CONTAINING THE DERIVATIVES, AND METHOD OF TREATING PARKINSON'S DISEASE USING THE SAME
EA201190207A1 (en) CONNECTIONS FOR THE TREATMENT OF METABOLIC DISORDERS
RU2014145931A (en) COMPOSITION FOR TREATING METABOLISM DISORDERS

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.